Philip Astley-Sparke Buys 31,000 Shares of enGene Therapeutics
Insider Philip Astley-Sparke purchases 31,000 shares of enGene Therapeutics, signaling confidence.
Key Points
- On June 16, 2026, Philip Astley-Sparke purchased 31,000 shares of enGene Therapeutics (ENGN) on NasdaqCM.
- Shares of enGene traded near $1.75 with a 52-week range between $1.40 and $12.25.
- enGene Therapeutics focuses on genetic medicines for bladder cancer, with a market cap of approximately $117.2 million.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 16, 2026, insider Philip Astley-Sparke purchased 31,000 shares of enGene Therapeutics Inc. (NasdaqCM: ENGN). This transaction did not specify a purchase price, but it highlights insider activity within the company.
enGene Therapeutics Inc. Stock Down 4.7%
Shares of enGene Therapeutics traded at about $1.75. The company, which operates in the biotechnology sector, has a market cap of approximately $117.2 million. enGene's stock has seen a 52-week low of $1.40 and a high of $12.25. The 50-day moving average is $4.33, while the 200-day moving average is $7.13. The company carries a strong current ratio of 12.57 and a quick ratio of 12.07, with a debt-to-equity ratio of 13.07.
About enGene Therapeutics
enGene Therapeutics Inc., based in Montreal, Canada, is a clinical-stage biotechnology company. It focuses on developing genetic medicines for patients with bladder cancer. The company’s lead product, detalimogene voraplasmid, is a monotherapy aimed at treating non-muscle invasive bladder cancer. enGene is also working on other projects such as LEGEND, which is in Phase 2 trials. Led by CEO Ronald H. W. Cooper, the company employs 81 people.
Bottom Line
Insider purchases like the one made by Philip Astley-Sparke can draw attention to a company and offer insights into insider confidence. enGene Therapeutics, with its focus on innovative genetic treatments for bladder cancer, remains a company to watch in the biotechnology sector. Keep in mind that this insider transaction is a backward-looking reflection of activity as of June 16, 2026, and may not represent the insider's current position.
Get enGene Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $ENGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.